- A company is conducting clinical trials and seeking drug approval for the U.S. market under the FDA.
A study involving Sue Sisley is progressing, having received taxpayer funding from the state legislature and facing the FDA's licensing requirements.
1 report, 1 independent
Updated Jun 5
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
A study involving Sue Sisley is progressing, having received taxpayer funding from the state legislature and facing the FDA's licensing requirements.
Who's involved
What this event is mainly aboutKeep exploring
Part of
A company is conducting clinical trials and seeking drug approval for the U.S. market under the FDA.Also in this story
- A partnership with BARDA has accelerated the development of SCY-247 for the company.
- A company plans to submit regulatory applications to the FDA, EMA, and Australian TGA.
- Approval leads to procurement process initiation.
- UroGen Pharma Ltd., headquartered in Princeton, is seeking FDA approval for its products for the U.S. market.
The entities involved
Related events
- An Arizona physician urges the FDA to declare a product shortage.
- FDA approval expands patient access to therapies for ACCORD.
- FDA approved a medical device from Abbott and supported a PARADIGM study based on data from the Cleveland Clinic.
- FDA approval preceded a device showcase event held in Las Vegas on October 13, 2026.